UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

The use of granulocyte colony-stimulating factors in a Canadian outpatient setting

Current oncology (Toronto), 2014-04, Vol.21 (2), p.e229-240

2014

Volltextzugriff (PDF)

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

Current oncology (Toronto), 2019-12, Vol.26 (6), p.e748-754

2019

Volltextzugriff (PDF)

Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Value in health, 2015-05, Vol.18 (3), p.A304-A305

2015

Volltextzugriff (PDF)

Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Value in health, 2015-05, Vol.18 (3), p.A168-A168

2015

Volltextzugriff (PDF)

THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.233-233

2016

Volltextzugriff (PDF)

2132 Retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

European journal of cancer (1990), 2015-09, Vol.51, p.S376-S376

2015

Volltextzugriff (PDF)

COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

Value in health, 2016-05, Vol.19 (3), p.A229-A230

2016

Volltextzugriff (PDF)

AB0389 Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.659-659

2013

Volltextzugriff (PDF)

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.240

2014

Volltextzugriff (PDF)

FRI0161 Response to etanercept-methotrexate therapy and etanercept monotherapy in rheumatoid arthritis patients with moderate and severe disease in the cameo trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A425-A426

2013

Volltextzugriff (PDF)

Comparaison de l’augmentation de la dose et de l’intensification du traitement d’association chez les patients atteints de polyarthrite rhumatoïde qui amorcent un traitement biologique par l’étanercept, l’adalimumab et l’infliximab

Revue du rhumatisme (Ed. française : 1993), 2016-11, Vol.83, p.A187-A188

2016

Volltextzugriff (PDF)

Différences de gravité du psoriasis chez des sujets atteints ou non de rhumatisme psoriasique et traités par l’étanercept

Annales de dermatologie et de vénéréologie, 2012-12, Vol.139 (12), p.B283-B284

2012

Volltextzugriff (PDF)

PSY74 - Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Value in health, 2015-05, Vol.18 (3), p.A304-A305

2015

Volltextzugriff (PDF)

PMS88 - Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Value in health, 2015-05, Vol.18 (3), p.A168-A168

2015

Volltextzugriff (PDF)

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-01

2018

Volltextzugriff (PDF)

PMS29 - COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

Value in health, 2016-05, Vol.19 (3), p.A229-A230

2016

Volltextzugriff (PDF)

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study: Table 1

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.240-240

2014

Volltextzugriff (PDF)

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5036-5036

2007

Volltextzugriff (PDF)

Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.LBA1-LBA1

2007

Volltextzugriff (PDF)

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3059-3059

2004

Volltextzugriff (PDF)

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3059-3059

2004

Volltextzugriff (PDF)

Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study

Canadian journal of kidney health and disease, 2018, Vol.5, p.2054358118778564-2054358118778564

2018

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)

Sprache

Englisch
(20)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Internal Medicine
(3)
Original
(3)
Life Sciences & Biomedicine
(2)
Oncology
(2)
Science & Technology
(2)
Anti
(1)
Biothérapie
(1)
Blood
(1)
Blood Transfusions
(1)
Chemotherapy
(1)
Colony-Stimulating Factors
(1)
Epidermal Growth Factor Inhibitor
(1)
Erythropoiesis-Stimulating Agent
(1)
Filgrastim
(1)
Hematology, Oncology And Palliative Medicine
(1)
Hemodialysis
(1)
Kras Testing
(1)
Neutropenia
(1)
Observational Studies
(1)
Outcomes
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The use of granulocyte colony-stimulating factors in a Canadian outpatient setting

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment

2132 Retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

AB0389 Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study

FRI0161 Response to etanercept-methotrexate therapy and etanercept monotherapy in rheumatoid arthritis patients with moderate and severe disease in the cameo trial

Comparaison de l’augmentation de la dose et de l’intensification du traitement d’association chez les patients atteints de polyarthrite rhumatoïde qui amorcent un traitement biologique par l’étanercept, l’adalimumab et l’infliximab

Différences de gravité du psoriasis chez des sujets atteints ou non de rhumatisme psoriasique et traités par l’étanercept

PSY74 - Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

PMS88 - Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

PMS29 - COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study: Table 1

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study

Aktive Filter

Suchergebnisse filtern